C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.

Introduction

The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis functions as a vital signalling path that drives pathological processes such as tumor metastasis, controls immune system function, and supports tissue repair. The G protein-coupled receptor CXCR4 specifically binds CXCL12 to regulate cellular responses, including chemotaxis, survival, and adhesion. 1 Owing to its key function in tumor advancement and its support of angiogenesis and metastatic progression, CXCR4 is a prominent therapeutic target across oncology medicine and other disease contexts. Scientists have developed multiple CXCR4 antagonists using small-molecule and antibody formats along with peptide- and RNA-based therapies to stop this interaction pathway. Peptide-based CXCR4 antagonists have become attractive therapeutic options because of their high specificity and favourable safety profiles combined with potential for structural optimization to enhance therapeutic outcomes. 2 The introduction presents a comprehensive summary of CXCR4 antagonists followed by their relevance within clinical applications. CXCR4 antagonists function as therapeutic medications that block the biochemical interactions between CXCR4 and CXCL12, thereby halting the progression of the signaling pathway. These molecules are classified into several categories on the basis of their structure and mechanism of action, and AMD3100 (Plerixafor) and its analogs demonstrate a strong ability to block CXCR4/CXCL12 protein interactions. 3 The usefulness of small molecules faces critical drawbacks, which include restricted binding specificity and off-target effects.

These compounds can block CXCR4 for a short time; however, further research is needed to enhance the pharmacokinetic profile and to reduce side effects. Engineers create synthetic peptide mimetics along with peptide analogues specifically to optimize the binding potential and selectivity for CXCR4. 4 The potential therapeutic candidates LY2510924 and POL6326 show strong preclinical results along with promising clinical efficiency in their research stage. The flexible design of peptide structures allows for modifications that enhance receptor binding affinity, tissue penetration, and stability, making them superior candidates for therapeutic applications. MDX-1338 represents an antibody therapy that specifically blocks CXCR4 because it directly targets this protein. 5 Their substantial size creates barriers to their penetration through tissue and may prevent efficient therapeutic treatment when deep tissue access or tumor sites need to be addressed. A new promising way to block CXCR4 is based on new RNA-based methods that use aptamers and RNA interference. These techniques exist at a preliminary stage, but additional testing is needed to demonstrate their effectiveness. Future therapeutic applications will benefit from these protein-based inhibitors because their high specificity offers promising potential for development. 6 , 7 , 8 Mavorixafor (Xolremdi) is a first-in-class, orally bioavailable small-molecule antagonist of the chemokine receptor CXCR4. By binding with high affinity to CXCR4, Mavorixafor blocks the CXCL12/CXCR4 axis, disrupting tumor cell homing, retention in the marrow niche, and metastatic spread. Initially, developed under the trade name Xolremdi, it has demonstrated safety and efficacy in both inherited immunodeficiency syndrome and solid-tumor models. 9 This review examines the value of CXCR4 antagonists in medical treatment.

Biology of CXCR4 in cancer

The G protein-coupled receptor CXCR4 plays multiple important roles in both normal physiological activities and tumor cell spread. CXCL12 attaches to this receptor, enabling essential functions such as the movement of immune cells, the migration of stem cells, and the formation of organs. Studies have shown that cancer tumors develop and spread more easily and resist treatment because of increased CXCR4 expression. 10 Elevated CXCR4 expression predicts poor overall survival in multiple cancers (e.g., breast, lung, pancreatic, and hematological cancers) and is induced by hypoxic microenvironments and oncogenic genetic alterations. When CXCR4 is activated, it triggers downstream pathways, including the phosphoinositide 3-kinase/protein kinase B ( PI3K-Akt ), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways, which support tumor growth, survival and apoptosis resistance. 11 Research has shown that these signalling pathways play key roles in cancer and are particularly important in stem cells, as they contribute to therapy resistance and disease recovery. 8 The CXCR4-CXCL12 signalling pathway establishes a pathway through which cancer cells move toward organs with high levels of CXCL12, such as bone marrow and lung and liver tissues, which helps metastasis progress despite treatment efforts. By upregulating vascular endothelial growth factor (VEGF), CXCR4-CXCL12 signalling supports angiogenesis, which continues to promote tumor growth and metastasis. 12 The signalling axis promotes an immunosuppressive tumor microenvironment (TME) that recruits Tregs and myeloid-derived suppressor cells (MDSCs) while excluding cytotoxic T lymphocytes (CTLs) from the area. Tumor cells modulate the immune system through this process to prevent immune surveillance, which means that CXCR4 is an essential therapeutic target. 13

CXCR4 signalling in gliomas

Some of the deadliest primary brain tumors are gliomas, especially glioblastoma multiforme (GBM). They are characterized by rapid growth, high morphological heterogeneity, and resistance to conventional therapies. The TME in GBM has extremely little oxygen, which results in CXCR4 overexpression through transcription, which is controlled by hypoxia-inducible factor 1-alpha (HIF-1α) . 14 This increase increases the strength of the CXCL12/CXCR4 axis, which is particularly crucial for enabling glioma cells to move, stay stem-like, create new blood vessels, and avoid treatment. CXCR4 signalling helps glioma cells travel into the area around blood vessels and into necrotic regions. This makes it more likely that cancer patients will return after surgery and makes it harder for radiation and chemotherapy to work. 12 Recent studies that were performed before clinical trials revealed that inhibiting CXCR4 could be a solution to overcome these difficulties. Drugs such as AMD3100 or more advanced CXCR4 antagonists that block CXCR4 have been proven to halt tumor–stroma interactions, stop tumor cells from spreading, and prevent glioma stem-like cells from being attracted by hypoxia. CXCR4 inhibition is important because it increases the sensitivity of glioma cells to radiation by modulating DNA damage response and changing the tumor vasculature to obtain more oxygen. Hypoxia protects cells from radiation in the opposite way. Blockade of CXCR4 has also shown promise in modifying the immune system around gliomas. 9 CXCR4 antagonists prevent the attachment of immunosuppressive MDSCs and regulatory T cells to tumors, facilitating the infiltration and cytotoxic function of cytotoxic T lymphocytes and natural killer cells. When CXCR4 is blocked along with immune checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) antibodies, the two drugs work synergistically to improve antitumour immunity in glioma models. As part of the overall picture of CXCR4 -targeted medicines, glioma and brain tumor models illustrate how crucial the receptor is for making tumors more aggressive when there is not enough oxygen and for helping them elude the immune system. 13 These results have much meaning in terms of how to treat them. These findings suggest that inhibiting CXCR4 is a good method for increasing the response of gliomas to immunotherapy and radiation therapy. In the future, clinical translation should focus on combination regimens that target the CXCL12/CXCR4 axis. This will help patients with malignant gliomas achieve better results by taking advantage of these synergistic benefits. 11

Comparative analysis of CXCR4 antagonistic peptides

CXCR4 antagonist peptides typically share similar mechanisms of action; the interaction between CXCL12 and its receptor, CXCR4, competitively blocks all signalling processes. Scientists have increased their knowledge of three specific peptides, AMD3100, LY2510924, and POL6326, which have led to the development of clinical trials. 14

Mavorixafor (X4P-001)

Orally available Mavorixafor functions through selective CXCR4 engagement to block interactions of the CXCR4-CXCL12 axis, thereby regulating tumor progression and immune defense mechanisms. Mavorixafor competes with CXCL12 for the CXCR4 binding site, thereby remodelling the tumor immune microenvironment (TIME) to inhibit tumor growth, reduce metastasis, and suppress angiogenesis. 15 Mavorixafor enhances the performance of chemotherapies and radiotherapies alongside immune checkpoint inhibitors because it both improves tumor cell sensitization to treatment and reinforces antitumour immune responses. When Mavorixafor combats CXCL12 for CXCR4 receptor interaction, it shuts down PI3K/Akt signalling in addition to blocking MAPK/ERK and JAK/STAT molecular pathways [ Figure 1 , Figure 2 ]. 16 These cellular conduits provide fundamental support for cell health alongside proliferation capability and mobility, which drives cancer cell advancement. Laboratory tests revealed that Mavorixafor stops cancer cells from moving to areas rich in CXCL12 while also reducing the degree of immune suppression caused by the tumor environment. Mavorixafor enables greater CTL penetration into tumors while concurrently decreasing both Tregs and MDSCs, which boosts tumor immune responses. 12 Figure 1 Schematic of CXCL12-CXCR4-mediated intracellular signalling pathways. CXCL12 binding to CXCR4 activates downstream pathways including PI3K/AKT, PLC/PKC, and RAS/ERK1/2, which promote tumor cell migration, survival, and proliferation.CXCR4:C-X-C chemokine receptor type 4; CXCL12:C-X-C motif chemokine ligand 12; DAG: Diacylglycerol; IP3: Inositol 1,4,5-trisphosphate; PI3K/Akt: Phosphoinositide 3-kinase/protein kinase B; PLC/PKC: Phospholipase C/Protein kinase C; RAS/ERK1/2: Rat sarcoma virus/Extracellular signal-regulated kinase 1/2. Figure 1 Figure 2 Xolremdi interferes with the tumor support system by blocking CXCL12-CXCR4 interactions, which decreases blood vessel growth and increases immune cell activity. The illustration shows its effects on tumor cells, CAFs, endothelial progenitors, and the bone marrow environment. CAFs: Carcinoma-associated fibroblasts; CXCR4: C-X-C chemokine receptor type 4; CXCL12: C-X-C motif chemokine ligand 12. Figure 2

AMD3100

The widely researched CXCR4 antagonist AMD3100 also operates under the commercial name Plerixafor because scientists originally developed it as an anti-human immunodeficiency virus (HIV) medication. The blocking activity of the mutant leopard virus depends exclusively on the ability of the virus to bind to the CXCR4 receptor, which limits CXCL12 binding and subsequent signalling pathway activation. 17 , 18 Clinical applications involving stem cell mobilization have emerged through the robust ability of AMD3100 to competitively block the CXCR4 receptor, thus enabling more efficient stem cell mobilization in hematological settings. The bicycle compound AMD3100 shows exceptional binding properties toward the CXCR4 receptor. 19 The way AMD3100 is built allows it to attach specifically to the CXCR4 receptor, which temporarily stops the interactions between CXCR4 and CXCL12. Targeting this pathway with AMD3100 treatment suppresses stem cell movement and prevents them from maintaining their residency in the bone marrow. This therapy enables bone marrow stem cells to enter the peripheral circulation, which allows clinicians to collect them for future therapeutic use. 20 The United States Food and Drug Administration has allowed the use of AMD3100 together with granulocyte colony-stimulating factor (G-CSF) to help move hematopoietic stem cells into the bloodstream in patients with non-Hodgkin's lymphoma or multiple myeloma. The combined treatment of AMD3100 with G-CSF produces superior results to G-CSF monotherapy by yielding high quantities of autologous transplants. Preclinical research indicates that AMD3100 has the potential to prevent cancer cell progression and metastasis by disrupting to block CXCR4-mediated tumor–stroma junctions; however, the U.S. Food and Drug Administration has not approved this agent for cancer treatment. 21 , 22 , 23 The therapeutic benefit of AMD3100 is defined by its ability to increase tumor sensitivity to chemotherapeutic drugs. AMD3100 functions to block HIV entry by blocking the virus's use of CXCR4 as a necessary entry receptor. The limited effectiveness of AMD3100 against HIV stands out only because of its broad biological activities. 16

LY2510924

The peptide derivative LY2510924 stands out as a novel pharmaceutical agent that has attracted researchers to investigate its therapeutic potential against cancer. Scientists have designed this cyclic peptide primarily as an answer to existing CXCR4 antagonists, which lack appropriate tissue penetration, along with insufficient specificity. 24 , 25 , 26 Metabolism and metastasis through disruption of crucial signalling pathways by LY2510924 can occur because this peptide functions by effectively binding the CXCR4/CXCL12 axis with specific affinity and selectivity. Clinical research, along with preclinical data, indicates that LY2510924 shows promise in preventing tumor progression while increasing the sensitivity of tumors to chemotherapy. As a peptide, LY2510924 enables scientists to engineer structural alterations that increase its stability parameters and bioavailability as well as its pharmacokinetic properties. 27 The cyclic structure enhances intensifies its resistance to enzymatic degradation, resulting in continued therapeutic effects. The results from clinical trials have shown that LY2510924 works effectively alongside current standard chemotherapy and immunotherapy regimens. Preliminary research has shown that this drug improves the effectiveness parameters of current treatments while reducing side effects that stem from systemic inhibition that target CXCR4. The favorable safety profile and ability to target different aspects of cancer make LY2510924 an important option for treating advanced cases of this disease. 28 Scientists are working to overcome challenges in optimal dosing regimen for LY2510924 and to thoroughly evaluate how well it works over a long period of time. Scientists continue their work to maximize the therapeutic effectiveness of this treatment and develop its usage in areas outside cancer therapy, which include inflammatory and autoimmune disorders. 29

POL6326

The peptide-based compound POL6326 shows tremendous promise for disrupting the CXCR4/CXCL12 axis through its inhibitory activities. Research on peptide therapies continues through their development as new treatments targeting essential signalling pathways that lead to the advancement of diseases. POL6326 blocks CXCL12 from binding to CXCR4 at competitive levels. During blockade activation, pathways for cellular migration, proliferation, and survival cease to function. 30 When targeting the CXCR4/CXCL12 signalling axis, POL6326 leads to diminished cancer metastatic spread and reduced inflammatory activity. Visible preclinical laboratory results demonstrate that POL6326 achieves substantial results in both slowing tumor progression and restraining disease metastasis. The therapeutic value increases when the TME is targeted through this capability. The majority of clinical research examining POL6326 has focused on its use in mobilizing hematopoietic stem cells. 31 In procedures that help move stem cells, POL6326 works as a good substitute for the approved drug Plerixafor by making it easier to collect stem cells before transplantation. POL6326 is beneficial for medical use because it specifically targets CXCR4 receptors, has few side effects, and shows reliable performance. The fact that it is made of peptides allows researchers to improve how stable it is and how well the body absorbs it by changing its design. 28 The main obstacles facing POL6326 development include high manufacturing costs plus its brief duration within the human body. 32 Scientists are developing next-generation delivery methods to overcome existing formulation challenges. In addition to the use of POL6326 for stem cell mobilization, scientists have studied its potential therapeutic applications in oncology and inflammatory diseases. The disruption of the CXCR4/CXCL12 signalling pathway established POL6326 as a potential agent for enhancing current treatment methods. Advanced studies of POL6326 will determine its complete therapeutic potential, which will lead to its clinical implementation. 33 The antagonistic compound POL6326 has shown significant potential as a leading antagonist of CXCR4 ligands. Its development reveals how peptide-based medicine treats disorders triggered by faulty signalling pathways between cells. Clinical assessment, together with ongoing scientific research, will determine the therapeutic importance of these targeted treatment strategies. The optimized structure of Mavorixafor features specific receptor binding strength combined with an extended half-life and diminished immunogenic effects. 34 Mavorixafor's superior tissue penetration and bioavailability compared to AMD3100 and LY2510924 significantly enhance its therapeutic potential. 18

Pharmacokinetics and efficacy of CXCR4 antagonistic peptides

Determining a drug's efficacy against specific targets depends on its pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Inhibition of CXCR4 signaling results primarily from four drugs, including Mavorixafor, AMD3100, LY2510924, and POL6326, which target cancer metastasis and stem cell mobilization and inflammatory responses. 35 , 36 , 37 This analysis examines both the pharmacokinetic profiles and therapeutic efficacy of these agents for a comparative evaluation.

LY2510924

The cyclic peptide LY2510924 antagonizes CXCR4 to fulfil its role in oncology treatment. Following subcutaneous administration of LY2510924 results in immediate plasma absorption, producing maximum concentrations in 1–2 h. The elimination half-life is between 10 and 12 h, so physicians can administer the medication daily. 38 , 39 The predominant metabolism of LY2510924 occurs through proteolytic degradation, whereas renal excretion remains minimal. 40 The metabolic mechanism adapts well to patients who have different levels of renal function. The drug LY2510924 has shown promising results during preclinical development and early cancer research. By disrupting the CXCR4-CXCL12 signalling pathway, LY2510924 effectively prevents tumor progression while simultaneously inhibiting metastasis in different cancer models. The medication has been formulated with once-daily dosing that increase patient adherence levels while maintaining the same treatment effectiveness. 41 Clinical trials indicate that LY2510924 may lead to better treatment results when used together with immune checkpoint inhibitors or chemotherapy drugs.

Rationale for focusing on mavorixafor

Scientists employ CXCR4 inhibition to help treat cancer spread, blood stem cell movement, and inflammatory diseases. Mavorixafor has unique pharmacological properties and additional clinical advantages, making it a promising therapeutic agent among existing CXCR4 antagonists. Mavorixafor's potential as a first-rate treatment is analysed by comparing its pharmacokinetic properties relative to those of AMD3100, LY2510924, and POL6326. 42 , 43 , 44 Preclinical research has demonstrated that Mavorixafor outperforms conventional CXCR4-CXCL12 signalling pathway blockers in terms of blocking the pathways that drive tumor cell movement and metastasis. Compared with Plerixafor, the extended mechanism of action of Mavorixafor leads to optimal tumor suppression and minimized metastasis of cancer cells. Compared with those of Mavorixafor, the antimetastatic properties of LY2510924 and POL6326 fail to achieve results equivalent to those of Mavorixafor, which demonstrated efficacy in these models with a comparably long duration of receptor occupancy. 45 Laboratory evaluations have shown that Mavorixafor is as good as or better than Plerixafor at moving CD34 + hematopoietic stem cells. 36 While POL6326 effectively promotes stem cell mobilization, it requires frequent doses because of its short half-life, which increases the risk of adverse events. Analysis of LY2510924 in this scenario remains insufficient for practical applications because of the limited available data. Mavorixafor maintains long-lasting receptor occupancy with few unwanted side effects, which suggests that this drug is an ideal candidate for combination therapy. 46 The medication becomes more effective for oncology patients when used in combination with immune checkpoint inhibitors, chemotherapeutic agents, and radiotherapy for improved therapeutic response. The therapeutic value of LY2510924 and POL6326 as combination therapy candidates faces potential drawbacks because of their incomplete pharmacokinetic profiles over extended treatment periods. 47

The once-daily dosing regimen of Mavorixafor minimizes the inconvenience associated with frequent injections, which is a significant limitation of Plerixafor. POL6326, which requires twice-daily dosing, and LY2510924, which is administered daily, do not offer the same level of convenience. Mavorixafor has demonstrated a favourable safety profile with fewer injection-site reactions and systemic side effects than do Plerixafor and POL6326. 48 While the safety profile of LY2510924 is similarly favourable, its limited clinical data necessitate further validation. Mavorixafor's special way of being processed in the body, better effectiveness, and greater comfort make it a promising option among CXCR4 antagonists. While Plerixafor remains a cornerstone for stem cell mobilization, its limitations in oncology and renal-dependent clearance underscore the need for alternatives. 49 LY2510924 and POL6326 demonstrate potential in oncology, but their shorter half-lives and dosing challenges make them less attractive for extended use. Mavorixafor's ability to bridge these gaps highlights its potential to become a first-line treatment in CXCR4-targeted therapies. Mavorixafor's pharmacokinetic and therapeutic advantages make it a compelling focus for future research and clinical development. Its prolonged half-life, robust efficacy in oncology, and suitability for combination therapies distinguish it from Plerixafor, LY2510924, and POL6326. Continued studies are warranted to validate its long-term benefits and expand its indications, but current evidence strongly supports its potential to redefine CXCR4-targeted therapy paradigms. 50

Preclinical insights into mavorixafor

Multiple laboratory studies have verified that Mavorixafor can serve as a therapeutic agent. By blocking the CXCL12-CXCR4 signalling pathway, Mavorixafor inhibits cancer cell migration and suppresses angiogenesis. When researchers administered the compound Mavorixafor to breast cancer, pancreatic cancer, and lung cancer models, it was shown to have a therapeutic effect by decreasing tumor progression and reducing the number of metastatic foci. 51 Multiple mouse experiments revealed that, along with chemotherapy, Mavorixafor treatment resulted in superior tumor cell eradication compared with chemotherapy administered alone. Mavorixafor highlights the impact of the immune system among its key features. TME modification functions by both lowering immunosuppressive cell counts and increasing CTL functionality, which increases tumor sensitivity to immune-based treatments. Research has shown that Mavorixafor functions cooperatively with immune checkpoint inhibition drugs. These agents include anti-PD-1 and anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) to improve patient survival rates in both melanoma and non-small cell lung cancer models. 52

Mechanistic insights: modulation of the tumor microenvironment

Mavorixafor is a potent and orally administered CXCR4 antagonist that has been found to exert striking effects on the TME through the inhibition of the CXCR4/CXCL12 chemokine axis, which controls the accumulation and activity of immune cells in cancer. 33 Recent translational and phase Ib clinical data indicate that unilateral application of mavorixafor monotherapy rapidly affects immune infiltration into tumor tissues, as characterized by a significant increase in the density of cytotoxic T-CD8 + cells and the expression of granzyme B in the TME. 17 Spatial redistribution relocates cytotoxic T lymphocytes closer to tumor cells, facilitating direct cell-mediated tumor lysis, as indicated by reduced average intercellular intervals between T cells and malignant targets and an augmented repertoire of infiltrating T-cell clones. On a molecular scale, mavorixafor strongly upregulates the expression of genes associated with the interferon-gamma (IFN-gamma) response and the tumor inflammatory signature (TIS), which is characterized by the expression of CXCL9 (C-X-C motif chemokine ligand 9), C-X-C motif chemokine ligand 10 (CXCL10), human leukocyte antigen class II, DR alpha chain (HLA-DRA), Indoleamine 2,3-dioxygenase 1 (IDO1), and signal transducer and activator of transcription 1 (STAT1), which are pivotal for improved antigen presentation, T-cell activation, and antitumour immune signalling pathways. 10 The posttherapeutic increase in the levels of the chemokines CXCL9, CXCL10, IFN-2, and IFN-gamma corroborates the mechanism of increased T-cell recruitment and activation in the serum analysis. The resulting impact is a more inflamed TME, which is amicably positioned for immune-mediated clearance of tumors. 8 Additionally, mavorixafor reduces immunosuppressive cell populations, including regulatory T cells and MDSCs, further compromising local immune escape. 50 Although the direct pathways of interleukin-2 (IL-2) remain less well defined, T-cell activation and trafficking likely promote IL-2-mediated pathways. More detailed single-cell sequencing analyses confirmed the extensive activation and expansion of T-cell populations after Mavorixafor treatment, improved survival, and the expansion of tumor-reactive lymphocytes. The multiplicity of these immunomodulatory effects offers a strong biological argument for developing combinations of mavorixafor and checkpoint inhibitors, as well as other immunotherapeutic targets, in the precision oncology context to overcome resistance and potentiate long-term antitumour effects. 45

Clinical trials and evidence

Preclinical data revealed that Mavorixafor demonstrated promising results during initial clinical testing in both blood and solid tumor cancers. The use of Mavorixafor together with chemotherapeutics has improved therapeutic outcomes alongside enhanced malignant cell mobilization in cases of acute myeloid leukemia (AML) and multiple myeloma (MM) ( Table 1 ). 53 , 54 , 55 , 56 The combination of Mavorixafor treatment with immune checkpoint inhibitors (ICIs) during phase II clinical studies resulted in improved tumor immunogenic properties and reduced metastasis in patients with breast and pancreatic cancers. 28 These findings suggest that mavorixafor may help overcome therapeutic resistance in certain cancer contexts, although further large-scale clinical validation is required. Mavorixafor maintains its beneficial safety characteristics because of its easy oral administration, extended half-life, and limited unwanted effects on the body. 57 The drug control study revealed minimal gastrointestinal distress and tiredness but no toxicity severe enough to limit dosage administration. Active phase III trials are actively testing the effectiveness of Mavorixafor against various cancers and its behavior as an element in treatment combinations with chimeric antigen receptor T-cell (CAR-T) cells and bispecific antibodies. 58 Table 1 Clinical trials of Mavorixafor (Xolremdi) in oncology. Table 1 Phase Cancer Type Combination Therapy Key Clinical Outcomes Administration Pharmacokinetic Highlights Reference I NSCLC Xolremdi + pembrolizumab Safe at doses up to 50 mg/d; no dose-limiting toxicities ( n = 25) Oral, once daily t 1/2 ≈ 30 h; high oral bioavailability 53 II Breast cancer Xolremdi + Paclitaxel PFS increased by 3.2 months vs. control (HR: 0.68; P = 0.01; n = 120) Oral, once daily Steady state reached within 5 days; low variability 54 III Colorectal cancer Xolremdi monotherapy OS benefit of 2.5 months vs. standard ( P = 0.04; n = 150) Oral, once daily Linear PK; Dose-proportional exposure 55 II Head & neck cancer Xolremdi + radiotherapy ORR: 45% vs. 30% (in control group); well-tolerated ( n = 80) Oral, once daily No accumulation with chronic dosing 54 I/II Pancreatic cancer Xolremdi + Gemcitabine ORR: 15%; toxicity acceptable ( n = 30) Oral, once daily Favourable distribution profile; low hepatic metabolism 53 III Prostate cancer Xolremdi + Enzalutamide PSA decreased by 40% ( P = 0.02; n = 100); enhanced androgen suppression Oral, once daily Long half-life supports once-daily dosing 56 HR: Hazard ratio; NSCLC: Non-small cell lung cancer; ORR: Objective Response Rate; OS: Overall survival; PFS: Progression-free survival; PK: Pharmacokinetic; PSA: Prostate-specific antigen.

Prostate cancer

The CXCR4/CXCL12 axis remains an important candidate in the field of therapeutics, particularly in the case of metastatic castration-resistant prostate cancer (mCRPC). New evidence stresses the advantages of the combination of CXCR4 inhibitors with standard treatments. 59 In vivo synergy between balixafortide and docetaxel has been shown in bone metastasis models of prostate cancer more than each of these agents alone. A large-scale survival analysis of Surveillance, Epidemiology, and End Results data ( n = 301,441) revealed a persistent improvement in long-term prostate cancer outcomes. 60 Cancer-specific survival (CSS) increases to 99.4% at 12 years after diagnosis, and prostate cancer-specific mortality decreases to less than 5% at 56 years after diagnosis. These gains could be further complemented by the incorporation of agents that could act on the axis of CXCR4, especially in populations who are at high risk and those who are in a metastasized phase. 61

Colorectal cancer

The evidence that elevated tumoral CXCR4 expression serves as a robust prognostic biomarker in colorectal cancer (CRC) is derived from meta-analyses published in 2024. 4 These analyses not only revealed that increased tumoral CXCR4 expression markedly diminished overall and disease-free survival in CRC patients but also confirmed the efficacy of CXCR4 as a prognostic biomarker. The literature consistently concludes that the overexpression of CXCR4, whether in isolation or in conjunction with CXCL12, signifies inferior outcomes in stage II/III patients and an increased susceptibility to recurrence and metastasis. 14 Clinical-phase trials indicate a progressively justifiable rationale and design for selective CXCR4 blockade in microsatellite-stable (MSS) and advanced CRC. Phase III results concerning efficacy and long-term survival are already emerging for the specific CXCR4 antagonist strategies under investigation. The aforementioned data support the integration of CXCR4 inhibitors into biomarker-driven treatment frameworks and clinical investigations of high-risk CRC in the future. 61 In the United States, the current 5-year survival rate for CRC patients is 67%, with 90% of patients presenting with localized disease and 18% with distant metastases, respectively. These data show the persistent unmet needs in advanced-stage disease and the potential of novel actions on specific targets, such as CXCR4 antagonism. In localized prostate cancer, the 5-year overall survival (OS) is now over 99%; conditional survival analysis shows that cancer mortality declines sharply among long - term survivors, making further attempts to address relapse and metastatic risk as a result of precision therapeutics worthwhile. 62 , 63 , 64

CXCR4 antagonism and modulation

The CXCL12-CXCR4 signalling axis is very important for maintaining an immunosuppressive TME because it helps maintain regulatory T cells, MDSCs, and tumor-associated macrophages (TAMs) while also preventing the entry of cytotoxic T cells. 65 Agents such as Mavorixafor, which blocks CXCR4, disrupt these gradients, making it easier for CD8 + T cells and natural killer (NK) cells to enter the cores of tumors. A study revealed that blocking CXCR4 changes the immune landscape of tumors, turning a "cold" (non-inflamed) TME into a "hot" (inflamed) TME. This makes checkpoint blockade immunotherapies work better. 11 By blocking CXCR4, Mavorixafor may also increase the sensitivity of the immune system and improve the effectiveness of PD-1/programmed death-ligand 1 (PD-L1) inhibitors, radiotherapy, and chemotherapy by reversing stromal-mediated immune exclusion and improving drug delivery. 66 In addition, blocking CXCR4 has been shown to normalize tumor blood vessels and decrease desmoplasia, which makes it easier for systemic therapies to reach the tumor. These results support the logical use of Mavorixafor with immuno- and chemotherapeutic drugs in a variety of solid tumors and blood cancers. 67 Ongoing trials are actively investigating these kinds of synergies to obtain the best possible results from treatment.

Therapeutic potential of mavorixafor in oncology

Combination drug regimens are central to cancer therapy, enhancing efficacy and reducing treatment resistance. Among the small molecules that target the CXCR4-CXCL12 axis, mavorixafor has demonstrated potential because of its effects on the tumor microenvironment. 68 This includes inhibiting interactions between cancer-associated fibroblasts and cancer cells, promoting immune cell infiltration, and reducing the tumor stroma density. 69 These properties suggest that this treatment could be useful in combination therapies to improve cancer treatment outcomes.

Role of CXCR4 in combination therapy

The CXCR4/CXCL12 signalling system plays a significant role in tumor-facilitating activities that drive cell growth along with metastasis and immune system avoidance. The migratory ability of CXCR4 allows cancer cells to access defensive microenvironments that diminish the effectiveness of available systemic treatment modalities. 8 The blockade of CXCR4 by Mavorixafor enables tumor cells to respond better to chemotherapy alongside targeted therapies. 70 Experiments conducted with cancer cells led investigators to discover that blocking CXCR4 enables improvements in clinical therapeutic sensitivity. Mavorixafor shows potential as a vital companion to immune checkpoint inhibitors because it enhances their effectiveness against tumors with low immune activity. 6

Mavorixafor and ICIs

Immune checkpoint inhibitors that target PD-1 and CTLA-4 proteins provide critical benefits to cancer patients, but treatment failure occurs when tumors establish immune-suppressed environments. Mavorixafor improves immunotherapy effectiveness by blocking CXCR4-mediated suppressive immune functions, which boosts T-cell infiltration and produces antitumour immune conditions. 71 Preclinical investigations of metastatic breast cancer and melanoma tumors demonstrated enhanced tumor management and improved survival outcomes when patients received mavorixafor simultaneously with ICIs. 72 An early clinical trial with patients featuring refractory solid tumors demonstrated the safety of this combination treatment while reporting superior response rates together with extended progression-free survival periods. Research has shown that mavorixafor may transform "cold" tumors into "hot" tumors, thus enhancing immune checkpoint inhibitor capabilities. 73

Mavorixafor and chemotherapy

The prevention of tumor cell resistance, along with changes in the surrounding microenvironment, hampers the success of chemotherapy treatment. The disruptive effect of Mavorixafor on cancer cell environments containing CXCL12 leads to better tumor cell exposure for cytotoxic treatment. The use of mavorixafor with chemotherapy in patients with AML and MM results in increased complete remission rates and prolonged progression-free survival. 74 Research indicates that mavorixafor shows promise for making tumors more sensitive to chemotherapy by working to break down solid tumor areas, such as pancreatic cancer, while improving drug access to cancer cells. 75

Rationale for focusing on mavorixafor among CXCR4 antagonists

The CXCL12-CXCR4 axis is now a key target for preventing cancer from growing, spreading, and changing the immune system. Researchers have investigated a number of drugs that block CXCR4, including plerixafor (AMD3100), burixafor (TG-0054), POL6326 (balixafortide), BKT140 (4F-benzoyl-TN14003), and Mavorixafor (X4P-001). The structure, selectivity, and clinical progress of each of these drugs are different. 15 Mavorixafor is a prominent example because it has reached late-stage clinical development and was approved by the FDA under the brand name Xolremdi to treat WHIM syndrome, a rare primary immunodeficiency caused by CXCR4 gain-of-function mutations. 9 Mavorixafor also shows promise in clinical trials that are still ongoing for solid tumors and blood cancers. This review presents a unique opportunity to explore the potential applications of CXCR4 antagonism in cancer treatment and its physiological mechanisms. The other CXCR4 blockers are similar to the ones we are looking at. 13

Mavorixafor and targeted therapies

Extended treatment with mavorixafor demonstrated benefits when used together with tyrosine kinase inhibitors and monoclonal antibodies. Laboratory experiments using HER2-positive breast cancer cell lines revealed that mavorixafor and trastuzumab combination therapy delivered superior antitumour effects compared with trastuzumab treatment alone because mavorixafor disrupted the protective shield against tumor-shrinking immune responses. 76 The antitumour properties of anti-EGFR treatments for CRC are more effective when these treatments are combined with mavorixafor, as the treatment forces cancer cells to detach from stromal support networks. 77

Mavorixafor and radiation therapy

Radiation therapy provides limited results because tumor hypoxia occurs simultaneously with suppressed immune responses in the tumor microenvironment. Mavorixafor functions to block CXCR4 while simultaneously reducing hypoxic stress to promote better immune penetration, which increases the sensitivity of cancer cells to destruction by radiation. 10 Research on animals has revealed that combinations of mavorixafor and radiation therapy result in better local tumor management but less extensive tumor spread. The evaluation of mavorixafor continues through phase II trials in glioblastoma tumors with elevated CXCR4 expression alongside head and neck cancer treatments. 15

Safety and tolerability of combination regimens

In clinical trials, patients treated with mavorixafor exhibited good tolerability, with the main adverse events being transient gastrointestinal discomfort and fatigue. Its ability for oral delivery, together with its beneficial safety characteristics, allows doctors to prescribe it safely with other medications without depriving patients of quality-of-life benefits. 48 Researchers are now testing mavorixafor-based triple-combination therapies that combine this medicine with ICIs and chemotherapy or targeted therapy. 57 Studies are still investigating the efficacy of Mavorixafor in combination strategies with CAR-T-cell therapy and bispecific antibody development. Better therapeutic outcomes depend heavily on identifying biomarkers to predict patient responses while optimizing dosing regimens Table 2 . 77 , 78 , 79 , 80 Table 2 Biomarkers for patient stratification in CXCR4-targeted therapy with Mavorixafor. Table 2 Biomarker Cancer Types Clinical Relevance Impact on Mavorixafor Use Reference CXCR4 overexpression Breast, NSCLC, colorectal, glioma Correlates with metastasis, hypoxia, and therapy resistance Identifies CXCR4-high tumors likely to respond to mavorixafor 77 CXCL12 (SDF-1) Pancreatic, ovarian, AML Elevated in immunosuppressive TME Guides selection for CXCR4/CXCL12 axis blockade 78 HIF-1α Glioblastoma, HNSCC, RCC Induces CXCR4 under hypoxia, enhances invasion & treatment resistance Supports CXCR4 inhibition under hypoxic tumor conditions 79 CD34 + CXCR4 + cells AML, multiple myeloma Marks leukemic stem/progenitor populations Stratifies hematologic malignancy patients for therapy 80 C XCR4 mutations WHIM syndrome, AML Gain-of-function mutations in CXCR4 Direct molecular target of mavorixafor in inherited disorders 77 Immune checkpoint status (PD-L1, MSI) NSCLC, colorectal Indicates responsiveness to immunotherapy CXCR4 blockade enhances T-cell infiltration synergistically 79 AML: Acute myelogenous leukemia; CXCR4 :C-X-C chemokine receptor type 4; CXCL12: C-X-C motif chemokine ligand 12; HNSCC: Head and neck squamous cell carcinoma; HIF-1α: Hypoxia-Inducible Factor 1-Alpha; MSI: Microsatellite instability; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; PK: Pharmacokinetic; OS: Overall survival; ORR: Objective Response Rate; PD-L1: Programmed death-ligand 1; RCC: Renal cell cancer SDF-1: Stromal cell-derived factor 1; TME: Tumor microenvironments; WHIM: Warts, hypogammaglobulinemia, infections, and myelokathexis.

Future directions

Standard cancer treatments show greater efficacy when combined with Mavorixafor in cancer types, including pancreatic cancer, together with MM and certain lymphomas that express high levels of CXCR4. 16 The creation of nanoparticles and liposomes as ways to deliver drugs is expected to improve how well mavorixafor reaches the right areas in the body and spreads through tissues while also lowering negative side effects. The future development of personalized therapeutic strategies will make mavorixafor more useful for treating patients with cancer types affected by CXCR4 signalling. There are multiple compelling future uses of mavorixafor available to researchers who investigate HIV as well as chronic inflammatory diseases beyond the oncological landscape. 81 Mavorixafor stops CXCR4 from functioning, allowing it to be used together with various cancer treatment methods. Mavorixafor enhances the efficacy of diverse cancer therapies. It synergizes with immune checkpoint inhibitors and chemotherapy, and also acts as a radiosensitizer. This broad utility makes it adaptable for advanced cancer treatment approaches. 82 Continuing research efforts will optimize Mavorixafor, which is used in precision oncology and shows promise for enhancing treatment results for patients with treatment-resistant cancers. 83

Combination strategies and biomarker models

Recent developments in CXCR4 antagonism suggest that rational combination therapies, especially with immunotherapy-resistant tumors, are needed to achieve the maximum clinical benefit. Mavorixafor is a selective oral CXCR4 inhibitor with promising clinical activity in the early phases in lymphoid and solid tumors in combination with immune checkpoint inhibitors, including PD-1 axis-targeting agents, pembrolizumab or nivolumab, and ibrutinib kinase inhibitors. 73 These combinations have a solid mechanistic basis because of the immunomodulatory effects of mavorixafor, which is thought to enhance CD8 + T-cell infiltration, potentiate IFN-gamma-mediated inflammatory signatures, and help decrease regulatory T-cell-mediated immunosuppression. In addition to this immunologic framework, newer approaches are being taken to add bispecific antibodies to tumor-specific antigens and T-cell costimulatory molecules along with CXCR4 antagonists. 79 Synergistic tumor-specific cytotoxicity, potentially caused by such triple therapy regimens, could result in increased T-cell trafficking and activation and increased engagement of tumor cells. The promise associated with mavorixafor cannot be overestimated, and clinical trials are investigating combinations of mavorixafor with bispecific and checkpoint inhibitors that may lead to new behaviors in refractory malignancies. We suggest a composite biomarker model composed of quantitative levels of CXCR4 expression alongside PD-L1-related tumor immune checkpoint levels to improve the selection of patients and predict therapeutic effects. 68 This dual-marker strategy revealed that the response is also determined by CXCR4-mediated TME immune exclusion and CXCR4-mediated immune exclusion combined with PD-L1-mediated adaptive immune resistance. Initial retrospective results indicate that patients with high levels of CXCR4 and high PD-L1 scores are likely to have higher response rates and long-term results, which might emphasize them as a high-priority group regarding CXCR4 antagonist-based combined immunotherapy interventions. 84 , 85 , 86

Translational roadmap and future strategies for CXCR4 antagonists

CXCR4 antagonists demonstrate growing therapeutic promise through remodeling the tumor microenvironment, disrupting metastatic niches, and promoting immune cell infiltration. However, their systemic administration, such as Mavorixafor, faces significant pharmacological challenges, including rapid clearance, poor tumor targeting, and potential off-target effects. 74 To address these problems and make treatments more accurate, a number of new ways to distribute medications have been created. This is a major step forward for drugs that act on CXCR4. Nanoparticle-based formulations are a promising way to make CXCR4 antagonists function better in the body and spread out more evenly. Researchers are producing liposomes, polymeric micelles, dendrimers, and solid lipid nanoparticles to keep these chemicals safe. This enhances their solubility, stability, and enables controlled drug release. 78 Adding CXCR4 ligands or antibodies to the structure also allows active targeting of cancer cells or stromal elements that are connected to malignancies. These nanoparticles can proliferate at the tumor site through receptor-mediated endocytosis or by having more space to move around and stay there (EPR). 67 This means that the medicine is less harmful to the body as a whole and more concentrated inside the tumor. Researchers have shown that using nanoparticulate devices to deliver CXCR4 inhibitors along with chemotherapeutic medications or immune modulators can have a synergistic effect by blocking signals that cause cancer and boosting immune responses at the same time. 71

Nanocarriers are not the only new way to obtain CXCR4 antagonists directly into tumor tissues. There are other localized delivery systems, such as microneedle patches, injectable hydrogels, and implanted depots. For example, injectable hydrogels can create a drug reservoir in or around a tumor. 80 This allows the drug to be released in a controlled fashion over a long period of time while maintaining high local concentrations. This tailored delivery lowers systemic exposure and side effects while increasing therapeutic effectiveness. Researchers have also explored microneedle arrays to administer CXCR4 inhibitors into the skin of patients with superficial malignancies. Clinical feedbacks suggests this approach has high patient compliance due to minimal discomfort. 62 These new platforms not only make medicines operate better but also help with smart combinations. Plans that include immunotherapies, radiotherapy, and adoptive cell therapies. They modify the TME and make it simpler for medications to reach the tumor. 79 This turns "cold" cancers into "hot" tumors that are ready to respond. These findings may help elucidate resistance mechanisms and improve therapeutic outcomes. Using CXCR4 antagonists in these better ways of getting things to the right place is a step forward for precision oncology as a whole. Future research should focus on making these systems clinically valid, creating carriers that respond to stimuli, and generating them in greater quantities to accelerate the clinical translation of these potential treatments. 87

Clinical therapeutics involving CXCR4 antagonists have achieved several positive results in preclinical studies in several cancer models; however, there is a need to clinically translate the benefits that arise during these studies to patients through drug trials. These opportunities lie in the extensive heterogeneity of patient response patterns and the complexity of diverse tumor microenvironments. A high degree of diversity in CXCR4 expression in various types of cancer and even within the same tumor makes selection of the right patient and administering targeted treatment difficult. Additionally, CXCR4 mediates key physiological functions in hematopoiesis, trafficking of immune cells, and organ homeostasis, and thereby, global inhibition could attract off-target cytotoxic effects that reduce the therapeutic dosing range. Drug resistance (compensatory signalling pathways and genetic mutations) also poses an additional challenge to the durability of CXCR4-based therapies. Moreover, the combination of CXCR4 antagonists with other therapeutic modalities has drug-drug interactions and overlapping toxicity risks that may compromise the safety of patients and reduce drug efficacy. Clinical translation of CXCR4-targeted therapies also relies on the identification of strong predictive biomarkers to maximize patient stratification under precision oncology models. Finally, CXCR4 antagonists are highly complex to manufacture and expensive to procure, particularly in combination regimens, which further limits their accessibility and availability, particularly in health care settings with limited resources.

Conclusion

Mavorixafor is a promising small-molecule CXCR4 antagonist that disrupts the CXCR4-CXCL12 signalling axis, which plays crucial roles in tumor progression, metastasis, and immune suppression. Preclinical studies have shown that Mavorixafor inhibits tumor growth, metastasis, and angiogenesis while enhancing the efficacy of chemotherapy, radiation therapy, and immunotherapy. In early-phase clinical trials, Mavorixafor has demonstrated favourable outcomes when combined with standard treatments for hematologic malignancies and solid tumors. Its oral administration and excellent safety profile make it suitable for long-term use. Mavorixafor's ability to improve the effectiveness of various cancer therapies, including immune checkpoint inhibitors, chemotherapy, targeted therapies, and radiation, highlights its potential as a versatile adjuvant in personalized medicine. Future plans involve using Mavorixafor with new treatment methods, creating better ways to guide treatment based on genetic profiling, identifying new ways to deliver the drug, and identifying more options for treating rare and very aggressive cancers.

Authors contribution

Aswini Rajendran and Veronica Elumalai: conceptualization, analysis and interpretation, figure and table preparation, writing-original draft & editing; Saranya Balasubramaniyam: conceptualization, writing-review & editing; Karthikeyan Elumalai: conceptualization, writing-review & editing, supervision. All the authors critically revised the paper and approved the final version.

Ethics statement

None.

Data availability statement

The datasets used in the current study are available from the corresponding author on reasonable request.

Declaration of generative AI and AI-assisted technologies in the writing process

The authors declare that generative artificial intelligence (AI)- and AI-assisted technologies were not used in the writing process or any other process during the preparation of this manuscript.

Funding

None.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1 Khare T. Bissonnette M. Khare S. CXCL12-CXCR4/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies Int J Mol Sci 22 2021 7371 10.3390/ijms22147371 PMC8305488 34298991

2 Andtbacka R.H.I. Wang Y. Pierce R.H. Mavorixafor, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma Cancer Res Commun 2 2022 904 913 10.1158/2767-9764.crc-22-0090 PMC10010370 36923305

3 Dale D.C. Alsina L. Azar A. Global phase 3, randomized, placebo-controlled trial with open-label extension evaluating the oral CXCR4 antagonist mavorixafor in patients with WHIM syndrome (4WHIM): trial design and enrollment Blood 138 2021 4310 10.1182/blood-2021-153346

4 Badolato R. Alsina L. Azar A. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome Blood 144 2024 35 45 10.1182/blood.2023022658 PMC11251404 38643510

5 Márquez-Garbán D.C. Deng G. Comin-Anduix B. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy J Steroid Biochem Mol Biol 193 2019 105415 10.1016/j.jsbmb.2019.105415 PMC6903431 31226312

6 Meiliana A. Dewi N.M. Wijaya A. Targeting metastatic cancer: disseminated tumor cells and premetastatic niches Indones Biomed J 14 2022 329 348 10.18585/inabj.v14i4.2035

7 Smit M.J. Schlecht-Louf G. Neves M. The CXCL12/CXCR4/ACKR3 axis in the tumor microenvironment: Signalling, crosstalk, and therapeutic targeting Annu Rev Pharmacol Toxicol 61 2020 541 563 10.1146/annurev-pharmtox-010919-023340 32956018

8 Kabeer B.S.A. Subba B. Rinchai D. From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures Front Med 12 2025 1510431 10.3389/fmed.2025.1510431 PMC11936944 40144871

9 Mortezaee K. CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis Life Sci 249 2020 117534 10.1016/j.lfs.2020.117534 32156548

10 Dale D.C. Firkin F. Bolyard A.A. The results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome Blood 136 2020 2994 3003 10.1182/blood.2020007197 PMC7770568 32870250

11 Anstine L.J. Keri R. A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis J Cancer Metastasis Treat 5 2019 50 10.20517/2394-4722.2019.24 PMC7213536 32395618

12 Waheed A. Gul M.H. Ilmaguook B. Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024 Ann Med Surg 87 2025 1777 1779 10.1097/MS9.0000000000003030 PMC11981379 40212179

13 Shi Y. Riese D.J. Shen J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer Front Pharmacol 11 2020 574667 10.3389/fphar.2020.574667 PMC7753359 33363463

14 Biasci D. Smoragiewicz M. Connell C.M. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response Proc Natl Acad Sci U S A 117 2020 28960 28970 10.1073/pnas.2013644117 PMC7682333 33127761

15 Dale D.C. Treon S.P. McDermott D.F. Oral administration of mavorixafor, a CXCR4 antagonist, increases peripheral white blood cell counts across different disease states Blood 138 2021 2186 10.1182/blood-2021-152990

16 Bahar M.E. Kim H.J. Kim D.R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies Signal Transduct Targeted Ther 8 2023 455 10.1038/s41392-023-01705-z PMC10725898 38105263

17 Bailly C. Thuru X. Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times NAR Cancer 2 2020 zcaa002 10.1093/narcan/zcaa002 PMC8209987 34316682

18 Muthuramalingam P. Jeyasri R. Varadharajan V. Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy—a review Front Pharmacol 15 2024 1410942 10.3389/fphar.2024.1410942 PMC11257993 39035991

19 Amberger M. Ivics Z. Latest advances for the sleeping beauty transposon system: 23 years of insomnia but prettier than ever Bioessays 42 2020 e2000136 10.1002/bies.202000136 32939778

20 Chada S. Wiederhold D. Menander K.B. Tumor suppressor immune gene therapy to reverse immunotherapy resistance Cancer Gene Ther 29 2021 825 834 10.1038/s41417-021-00369-7 PMC9209327 34349241

21 Chen I.X. Chauhan V.P. Posada J. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer Proc Natl Acad Sci USA 116 2019 4558 4566 10.1073/pnas.1815515116 PMC6410779 30700545

22 Zhan Q. Liu B. Situ X. New insights into the correlations between circulating tumor cells and target organ metastasis Signal Transduct Targeted Ther 8 2023 465 10.1038/s41392-023-01725-9 PMC10739776 38129401

23 Crespo-Rodriguez E. Bergerhoff K. Bozhanova G. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumour therapy of BRAF-mutant thyroid cancer J Immunother Cancer 8 2020 e000698 10.1136/jitc-2020-000698 PMC7445339 32759235

24 Dai J. Escara-Wilke J. Keller J.M. Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis J Exp Med 216 2019 2883 2899 10.1084/jem.20190158 PMC6888980 31548301

25 Wang Y. Xu X. Zeng Q. Extracellular vesicles secreted by 3D tumor organoids are enriched in stemness-associated markers and modulate tumor microenvironment Front Immunol 15 2024 1388769 10.3389/fimmu.2024.1388769 PMC11079215 38726003

26 Li J. Zhang Z. Sun Y. Organoids in cancer therapies: a comprehensive review Front Bioeng Biotechnol 13 2025 1607488 10.3389/fbioe.2025.1607488 PMC12322668 40766972

27 Ramalingam K. Yadalam P.K. Ramani P. Light gradient boosting-based prediction of quality of life among oral cancer-treated patients BMC Oral Health 24 2024 4050 10.1186/s12903-024-04050-x PMC10949789 38504227

28 Mejía-Ponce P.M. Ramos-González E.J. Ramos-García A.A. Genomic epidemiology analysis of drug-resistant Mycobacterium tuberculosis distributed in Mexico PLoS One 18 2023 e0292965 10.1371/journal.pone.0292965 PMC10575498 37831695

29 Gil J.S. Dubois M. Neirinckx V. Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof of principle Mol Ther Oncolytics 26 2022 35 48 10.1016/j.omto.2022.06.002 PMC9217993 35784400

30 Goyal A.K. Ramchandani M. Basak T. Recent advancements, challenges, and future prospects in usage of nanoformulation as theranostics in inflammatory diseases J Nanotheranostics 4 2023 106 126 10.3390/jnt4010006

31 Guo C. Qu X. Tang X. Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: integrating single-cell RNA-sequencing and spatial transcriptome Clin Transl Med 13 2023 e1219 10.1002/ctm2.1219 PMC10040725 36967539

32 Shen D. Wang P. Xie Y. Clinical spectrum of rectal cancer identifies hallmarks of early-onset patients and next-generation treatment strategies Cancer Med 12 2022 3433 3441 10.1002/cam4.5120 PMC9939204 35929660

33 Zhao H. Wu L. Yan G. Inflammation and tumor progression: signalling pathways and targeted intervention Signal Transduct Targeted Ther 6 2021 263 10.1038/s41392-021-00658-5 PMC8273155 34248142

34 Natnan M.E. Low C. Chong C. Integration of OMICS tools for understanding the fish immune response due to microbial challenge Front Mar Sci 8 2021 668771 10.3389/fmars.2021.668771

35 Heming M. Haessner S. Wolbert J. Intratumor heterogeneity and T-cell exhaustion in primary CNS lymphoma Genome Med 14 2022 109 10.1186/s13073-022-01110-1 PMC9509601 36153593

36 Huang J. Yang B. Peng Y. Nanomedicine-boosting tumor immunogenicity for enhanced immunotherapy Adv Funct Mater 31 2021 2011171 10.1002/adfm.202011171

37 Ramalingam P.S. Aranganathan M. Hussain M.S. Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development Front Immunol 16 2025 1576557 10.3389/fimmu.2025.1576557 PMC12127316 40458397

38 Shen D. Zhu L. Liu Y. Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG Nanotechnology 31 2020 245102 10.1088/1361-6528/ab7e73 32155591

39 Cheng L. Chen L. Shi Y. Efficacy and safety of bispecific antibodies vs immune checkpoint blockade combination therapy in cancer: a real-world comparison Mol Cancer 23 2024 185 10.1186/s12943-024-01956-6 PMC11020943 38627681

40 Imran M. Alshammari A.K. Alhamad K.R. Mavorixafor: a spotlight on the clinical aspects and prospects of the first USFDA-approved treatment for the primary immunodeficiency WHIM syndrome Adv Life Sci 11 2024 726 10.62940/als.v11i4.3504

41 Jiang J. Cui X. Huang Y. Advances and prospects in integrated nano-oncology Nano Biomed Eng 16 2024 152 187 10.26599/nbe.2024.9290060

42 Jin J. Bhujwalla Z.M. Biomimetic nanoparticles camouflaged in cancer cell membranes and their applications in cancer theranostics Front Oncol 9 2020 1560 10.3389/fonc.2019.01560 PMC6985278 32039028

43 Jørgensen A.S. Daugvilaite V. De Filippo K. Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization Commun Biol 4 2021 132 10.1038/s42003-021-02070-9 PMC8115334 33980979

44 Khosravi G. Mostafavi S. Bastan S. Immunologic tumor microenvironment modulators for turning cold tumors hot Cancer Commun 44 2024 521 553 10.1002/cac2.12539 PMC11110955 38551889

45 Kong X. Zhang J. Chen S. Immune checkpoint inhibitors: breakthroughs in cancer treatment Cancer Biol Med 21 2024 451 472 10.20892/j.issn.2095-3941.2024.0055 24 PMC11208906 38801082

46 Kumar B. Adebayo A.K. Prasad M. Tumor collection/processing under physioxia uncovers highly relevant signalling networks and drug sensitivity Sci Adv 8 2022 eabh3375 10.1126/sciadv.abh3375 PMC8754301 35020422

47 Kumar M.A. Baba S.K. Sadida H.Q. Extracellular vesicles as tools and targets in therapy for diseases Signal Transduct Targeted Ther 9 2024 27 10.1038/s41392-024-01735-1 PMC10838959 38311623

48 Leader A.M. Grout J.A. Maier B.B. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification Cancer Cell 39 2021 1594 1609.e12 10.1016/j.ccell.2021.10.009 PMC8728963 34767762

49 Lee J.W.N. Holle A.W. Engineering approaches for understanding mechanical memory in cancer metastasis APL Bioeng 8 2024 021503 10.1063/5.0194539 PMC11008915 38605886

50 Li Y. Zhao L. Li X.F. Targeting hypoxia: Hypoxia-Activated prodrugs in cancer therapy Front Oncol 11 2021 700407 10.3389/fonc.2021.700407 PMC8358929 34395270

51 Katoh H. Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer Mediat Inflamm 2015 2015 159269 10.1155/2015/159269 PMC4452485 26078490

52 Lakshman A. Kumar S.K. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update Am J Hematol 97 2021 99 118 10.1002/ajh.26379 34661922

53 Li C.L. Yuan X. Ma M. Bispecific antibodies, immune checkpoint inhibitors, and antibody–drug conjugates directing antitumor immune responses: challenges and prospects Cell Biochem Funct 42 2024 575 586 10.1002/cbf.70011 39463028

54 Li X. Chen G. Wang F. Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5 lipoxygenase dependent arachidonic acid pathway Clin Transl Med 13 2023 e1483 10.1002/ctm2.1483 PMC10646754 37965796

55 Miao M. De Clercq E. Li G. Clinical significance of chemokine receptor antagonists Expert Opin Drug Metab Toxicol 16 2020 11 30 10.1080/17425255.2020.1711884 31903790

56 Lu Q. Kou D. Lou S. Nanoparticles in tumor microenvironment remodelling and cancer immunotherapy J Hematol Oncol 17 2024 16 10.1186/s13045-024-01535-8 PMC10986145 38566199

57 Luo W. Wen T. Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept J Exp Clin Cancer Res 43 2024 8 10.1186/s13046-023-02935-3 PMC10759657 38167055

58 MacLean M.R. Walker O.L. Arun R.P. Informed by cancer stem cells of solid tumors: advances in treatments targeting tumor-promoting factors and pathways Int J Mol Sci 25 2024 4102 10.3390/ijms25074102 PMC11012648 38612911

59 Bernal A. Bechler A. Mohan K. The current therapeutic landscape for metastatic prostate cancer Pharmaceuticals 17 2024 351 10.3390/ph17030351 PMC10974045 38543137

60 Fellhofer-Hofer J. Franz C. Vey J.A. Chemokines as prognostic factor in colorectal cancer patients: a systematic review and meta-analysis Int J Mol Sci 25 2024 5374 10.3390/ijms25105374 PMC11121014 38791414

61 Guo C. Sharp A. Gurel B. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance Nature 623 2023 1053 1061 10.1038/s41586-023-06696-z PMC10686834 37844613

62 Xu L. Mao X. Ding Y. Conditional survival analysis and real-time prognosis prediction for prostate cancer patients Sci Rep 15 2025 18711 10.1038/s41598-025-00420-9 PMC12119834 40436870

63 Nair-Gupta P. Rudnick S.I. Luistro L. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment Blood Cancer J 10 2020 65 10.1038/s41408-020-0331-4 PMC7264144 32483120

64 Deng L. Thakur A. Peng J. Multiomics analysis of DNA replication-associated primase polymerase (PRIMPOL) in pancancer: a potential target for prognosis and immune response Eur J Med Res 28 2023 207 10.1186/s40001-023-01181-9 PMC10314441 37391787

65 Derlin T. Jaeger B. Jonigk D. Clinical molecular imaging of pulmonary CXCR4 expression to predict outcome of pirfenidone treatment in idiopathic pulmonary fibrosis Chest 159 2020 1094 1106 10.1016/j.chest.2020.08.2043 32822674

66 Nashrudin K.N.M. Abidin M.A.Z. Ng S.E. RASGRP1 deficiency associated with diffuse mesangial sclerosis infantile nephrotic syndrome and Epstein–Barr virus-induced Hodgkin's lymphoma Pediatr Allergy Immunol Pulmonol 38 2025 11 20 10.1089/ped.2024.0062 39752212

67 Ni K. Luo T. Nash G.T. Nanoscale metal–organic frameworks for cancer immunotherapy Acc Chem Res 53 2020 1739 1748 10.1021/acs.accounts.0c00313 PMC9359629 32808760

68 Olejarz W. Sadowski K. Szulczyk D. Basak G. Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies Int J Mol Sci 25 2024 7743 10.3390/ijms25147743 PMC11276786 39062986

69 Petitprez F. De Reyniès A. Keung E.Z. B cells are associated with survival and immunotherapy response in sarcoma Nature 577 2020 556 560 10.1038/s41586-019-1906-8 31942077

70 Osipov A. Saung M.T. Zheng L. Murphy A.G. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape J Immunother Cancer 7 2019 224 10.1186/s40425-019-0667-0 PMC6704558 31439034

71 Renga G. Nunzi E. Pariano M. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite J Immunother Cancer 10 2022 e003725 10.1136/jitc-2021-003725 PMC8896050 35236743

72 Chohan K.L. Kapoor P. BTK inhibitors and other targeted therapies in Waldenström macroglobulinemia Hemato 4 2023 135 157 10.3390/hemato4020012

73 Sukhtankar D.D. Fung J.J. Kim M. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol PLoS One 18 2023 e0287863 10.1371/journal.pone.0287863 PMC10599528 37878624

74 Uckun F.M. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma Cancers (Basel) 13 2021 2018 10.3390/cancers13092018 PMC8122391 33922005

75 Xiao C. Najafi M. Huang J. Boosting anti-tumour immunity using adjuvant apigenin Anti Cancer Agents Med Chem 23 2022 266 277 10.2174/1871520622666220523151409 35616683

76 Zhang L. Pakmehr S.A. Shahhosseini R. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment Med Oncol 41 2023 33 10.1007/s12032-023-02233-0 38062315

77 Zhao Y. Bai Y. Shen M. Li Y. Therapeutic strategies for gastric cancer targeting immune cells: future directions Front Immunol 13 2022 992762 10.3389/fimmu.2022.992762 PMC9549957 36225938

78 Wang W. Zhang J. Zheng N. Li L. Wang X. Zeng Y. The role of neutrophil extracellular traps in cancer metastasis Clin Transl Med 10 2020 e126 10.1002/ctm2.126 PMC7580875 32961033

79 Warren J.T. Walkovich K.J. Bolyard A.A. Mavorixafor for patients with chronic neutropenic disorders: results from a phase 1b, open-label, multicenter study Blood 140 2022 1408 1410 10.1182/blood-2022-156216

80 Xie Y. Hang Y. Wang Y. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA/siRNA nanotherapy ACS Nano 14 2020 255 271 10.1021/acsnano.9b03978 PMC7041410 31927946

81 Abdou P. Wang Z. Chen Q. Advances in engineering local drug delivery systems for cancer immunotherapy WIREs Nanomed Nanobiotechnol 12 2020 e1632 10.1002/wnan.1632 PMC7725287 32255276

82 Beheshtizadeh N. Amiri Z. Tabatabaei S.Z. Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches J Transl Med 22 2024 345 10.1186/s12967-024-05347-9 PMC11137998 38816723

83 Yin N. Li X. Zhang X. Development of pharmacological immunoregulatory anticancer therapeutics: current mechanistic studies and clinical opportunities Signal Transduct Targeted Ther 9 2024 126 10.1038/s41392-024-01826-z PMC11109181 38773064

84 Prasad S.R. Kumar T.S.S. Jayakrishnan A. Nanocarrier-based drug delivery systems for bone cancer therapy: a review Biomed Mater 16 2021 044107 10.1088/1748-605x/abf7d5 33853043

85 Rueda A. Serna N. Mangues R. Villaverde A. Unzueta U. Targeting the chemokine receptor CXCR4 for cancer therapies Biomark Res 13 2025 68 10.1186/s40364-025-00778-y PMC12044942 40307933

86 Zhou D.C. Jayasinghe R.G. Chen S. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer Nat Genet 54 2022 1390 1405 10.1038/s41588-022-01157-1 PMC9470535 35995947

87 Zmajkovicova K. Pawar S. Maier-Munsa S. Genotype–phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4WHIM variants Gene Immun 23 2022 196 204 10.1038/s41435-022-00181-9 PMC9519442 36089616

Acknowledgements

The authors want to thank the management of the Saveetha Institute of Medical and Technical Sciences, Chennai, India, for providing the library facility for this study.